Last reviewed · How we verify
etonogestrel with testosterone undecanoate
etonogestrel with testosterone undecanoate is a Small molecule drug developed by Organon and Co. It is currently in Phase 2 development.
At a glance
| Generic name | etonogestrel with testosterone undecanoate |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- etonogestrel with testosterone undecanoate CI brief — competitive landscape report
- etonogestrel with testosterone undecanoate updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about etonogestrel with testosterone undecanoate
What is etonogestrel with testosterone undecanoate?
etonogestrel with testosterone undecanoate is a Small molecule drug developed by Organon and Co.
Who makes etonogestrel with testosterone undecanoate?
etonogestrel with testosterone undecanoate is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).
What development phase is etonogestrel with testosterone undecanoate in?
etonogestrel with testosterone undecanoate is in Phase 2.